Your browser doesn't support javascript.
loading
Toxoplasmosis in non-cardiac solid organ transplant recipients: A case series and review of literature.
Ramanan, Poornima; Scherger, Sias; Benamu, Esther; Bajrovic, Valida; Jackson, Whitney; Hage, Chadi A; Hakki, Morgan; Baddley, John W; Abidi, Maheen Z.
Afiliação
  • Ramanan P; Division of Infectious Disease, University of Colorado Denver, Denver, CO, USA.
  • Scherger S; Division of Infectious Disease, University of Colorado Denver, Denver, CO, USA.
  • Benamu E; Division of Infectious Disease, University of Colorado Denver, Denver, CO, USA.
  • Bajrovic V; Division of Infectious Disease, University of Colorado Denver, Denver, CO, USA.
  • Jackson W; Division of Gastroenterology and Hepatology, University of Colorado Denver, Denver, CO, USA.
  • Hage CA; Division of Pulmonary and Critical Care Medicine, Thoracic Transplantation Program, Indiana University School of Medicine, Indianapolis, IN, USA.
  • Hakki M; Division of Infectious Disease, Oregon Health and Sciences University, Portland, OR, USA.
  • Baddley JW; Division of Infectious Disease, University of Alabama, Birmingham, AL, USA.
  • Abidi MZ; Division of Infectious Disease, University of Colorado Denver, Denver, CO, USA.
Transpl Infect Dis ; 22(1): e13218, 2020 Feb.
Article em En | MEDLINE | ID: mdl-31769583
ABSTRACT
The risk of toxoplasmosis in high-risk cardiac transplant recipients is well recognized prompting universal donor and candidate screening with administration of targeted post-transplant chemoprophylaxis in high-risk (D+/R-) cardiac transplant patients. In contrast, until recently, there have been neither well-defined recommendations nor consensus regarding toxoplasmosis preventive strategies among non-cardiac solid organ transplant recipients. We report 3 cases of post-transplant toxoplasmosis in non-cardiac transplant recipients (one lung and two liver); all 3 infections presumed to be donor-derived. Not surprisingly, pre-transplant Toxoplasma serology was negative in all the patients. None of the patients were on trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis at the time of diagnosis of toxoplasmosis. The median time from transplant to onset of infection was 90 days (range 30-120 days). Clinical presentations included cerebral (n = 1) and disseminated infections (n = 2). Two of the 3 patients, both with disseminated infection died (mortality ~ 67%).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 3_ND Base de dados: MEDLINE Assunto principal: Doadores de Tecidos / Toxoplasmose / Transplante de Fígado / Transplante de Pulmão / Transplantados Tipo de estudo: Diagnostic_studies / Guideline Limite: Adult / Humans / Male / Middle aged Idioma: En Revista: Transpl Infect Dis Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 3_ND Base de dados: MEDLINE Assunto principal: Doadores de Tecidos / Toxoplasmose / Transplante de Fígado / Transplante de Pulmão / Transplantados Tipo de estudo: Diagnostic_studies / Guideline Limite: Adult / Humans / Male / Middle aged Idioma: En Revista: Transpl Infect Dis Ano de publicação: 2020 Tipo de documento: Article